Skip to search formSkip to main contentSkip to account menu

SGN-19A

Known as: ADC SGN-19A, SGN-CD19A 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Denintuzumab Mafodotin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Abstract 1339: Preclinical combination activity of SGN-CD19A and CVAD in patient-derived B-lineage acute lymphoblastic leukemia models
Combining targeted therapies with standard of care chemotherapy is a proven method for improving outcomes for cancer patients… 
2014
2014
Abstract DDT01-04: SGN-CD19A: A novel Anti-CD19 antibody drug conjugate
CD19, a member of the immunoglobulin superfamily, is a B-cell specific marker that is found on B cells as early as the pro-B cell… 
2014
2014
Abstract 4642: Model-based alternative clinical trial designs and evaluations for SGN-CD19A, a novel antibody-drug conjugate
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background SGN-CD19A is a novel antibody-drug conjugate… 
2011
2011
Abstract 625: Preclinical characterization of an auristatin-based anti-CD19 drug conjugate, SGN-19A
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL CD19 has multiple attributes that make it an attractive… 
2011
2011
Abstract 1789: Auristatin-based antibody-drug conjugates are synergistic in combination with PI3K-AKT-mTOR pathway inhibitors in hematologic malignancies and carcinoma
Antibody-drug conjugates (ADCs) that couple the potent anti-mitotic agents monomethyl auristatin E or F (MMAE or MMAF) to tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)